Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.
Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative "Making more Health" and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.
In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its net sales.
Business & Industry
- Merck initiates first clinical trial of TLR7 and 8 inhibitor as a potential treatment for severe symptoms of COVID-19 infection
- Novartis resolves legacy litigation matters, finalizing settlement of speaker program litigation with Government in the US
- Pfizer and BioNTech announce early positive data from an ongoing Phase 1/2 study of mRNA-based vaccine candidate against SARS-CoV-2
- Lilly begins world's first study of a potential COVID-19 antibody treatment in humans
- GSK COVID-19 vaccine development collaboration with Clover Biopharmaceuticals begins clinical trials
Research & Development
- Newer variant of COVID-19-causing virus dominates global infections
- Researchers identify multiple molecules that shut down SARS-Cov-2 polymerase reaction
- Whole-town study reveals more than 40% of COVID-19 infections had no symptoms
- Even in the worst COVID-19 cases, the body launches immune cells to fight back
- Existing drugs can prevent SARS-CoV-2 from hijacking cells
- Study is first to identify potential therapeutic targets for COVID-19
- Initial COVID-19 infection rate may be 80 times greater than originally reported
Conferences & Events
- Wearable Injectors and Connected Devices Conference 2020
- Preparing for the new world of drug safety: Embracing cloud and AI
- Pre-filled Syringes San Francisco Conference 2020
- Oligonucleotide Therapeutics and Delivery Conference 2020
- Pre-Filled Syringes West Coast 2021
- Pre-Filled Syringes East Coast Conference 2020
- SMi's 4th Annual Pharmaceutical Microbiology West Coast
Regulatory Affairs
- FDA Takes Action to Help Facilitate Timely Development of Safe, Effective COVID-19 Vaccines
- FDA announces first of its kind pilot program to communicate patient reported outcomes from cancer clinical trials
- FDA revokes emergency use authorization for chloroquine and hydroxychloroquine
- Global regulators commit to cooperate on observational research in the context of COVID-19
- FDA takes new actions to accelerate development of novel prevention, treatment options for COVID-19